Advances in epigenetic therapies for B-cell non-hodgkin lymphoma

被引：1

作者：

Hu, Weiwen ^{[1
,2
]}

Zang, Lanlan ^{[3
]}

Feng, Xiaoxi ^{[1
,2
]}

Zhuang, Shuhui ^{[1
,2
]}

Chang, Liudi ^{[1
,2
]}

Liu, Yongjing ^{[4
]}

Huang, Jinyan ^{[4
]}

Zhang, Yuanyuan ^{[2
]}

机构：

[1] Shandong Second Med Univ, Sch Clin Med, Weifang 261053, Shandong, Peoples R China

[2] Shandong Second Med Univ, Linyi Peoples Hosp, Dept Hematol, Linyi 276000, Shandong, Peoples R China

[3] Shandong Second Med Univ, Linyi Peoples Hosp, Dept Pharm, Pharmaceut Lab, Linyi 276000, Shandong, Peoples R China

[4] Zhejiang Univ, Biomed Big Data Ctr, Sch Med, Affiliated Hosp 1, Hangzhou 311121, Peoples R China

来源：

ANNALS OF HEMATOLOGY | 2024年 / 103卷 / 12期

关键词：

Epigenetics; B-NHLs; Epigenetic drugs; Targeted therapy; DNA METHYLATION; FOLLICULAR LYMPHOMA; SIGNALING PATHWAY; GERMINAL CENTER; OPEN-LABEL; EXPRESSION; CHROMATIN; PROLIFERATION; PROGRESSION; SUPPRESSOR;

D O I：

10.1007/s00277-024-06131-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

B-cell non-Hodgkin lymphomas (B-NHLs) constitute a varied group of cancers originating from B lymphocytes. B-NHLs can occur at any stage of normal B-cell development, with most arising from germinal centres (e.g. diffuse large B-cell lymphoma, DLBCL and follicular lymphoma, FL). The standard initial treatment usually involves the chemoimmunotherapy regimen. Although there is a high initial response rate, 30-40% of high-risk patients often face relapsed or refractory lymphoma due to drug resistance. Recent research has uncovered a significant link between the development of B-NHLs and various epigenetic processes, such as DNA methylation, histone modification, regulation by non-coding RNAs, and chromatin remodeling. Therapies targeting these epigenetic changes have demonstrated considerable potential in clinical studies. This article examines the influence of epigenetic regulation on the onset and progression of B-NHLs. It discusses the current therapeutic targets and agents linked to these epigenetic mechanisms, with the goal of offering new perspectives and approaches for targeted therapies and combination chemotherapy in treating B-NHLs.

引用

页码：5085 / 5101

页数：17

共 165 条

[1] Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma [J].

Agarwal, Rishu ;

Chan, Yih-Chih ;

Tam, Constantine S. ;

Hunter, Tane ;

Vassiliadis, Dane ;

Teh, Charis E. ;

Thijssen, Rachel ;

Yeh, Paul ;

Wong, Stephen Q. ;

Ftouni, Sarah ;

Lam, Enid Y. N. ;

Anderson, Mary Ann ;

Pott, Christiane ;

Gilan, Omer ;

Bell, Charles C. ;

Knezevic, Kathy ;

Blombery, Piers ;

Rayeroux, Kathleen ;

Zordan, Adrian ;

Li, Jason ;

Huang, David C. S. ;

Wall, Meaghan ;

Seymour, John F. ;

Gray, Daniel H. D. ;

Roberts, Andrew W. ;

Dawson, Mark A. ;

Dawson, Sarah-Jane .

NATURE MEDICINE, 2019, 25 (01) :119-+

[2] Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas [J].

Amara, K. ;

Trimeche, M. ;

Ziadi, S. ;

Laatiri, A. ;

Hachana, M. ;

Korbi, S. .

ANNALS OF ONCOLOGY, 2008, 19 (10) :1774-1786

[3] MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12 [J].

An, Licai ;

Li, Xijing ;

Yang, Jing .

LEUKEMIA RESEARCH, 2021, 110

[4] Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo [J].

Anastasiadou, Eleni ;

Seto, Anita G. ;

Beatty, Xuan ;

Hermreck, Melanie ;

Gilles, Maud-Emmanuelle ;

Stroopinsky, Dina ;

Pinter-Brown, Lauren C. ;

Pestano, Linda ;

Marchese, Cinzia ;

Avigan, David ;

Trivedi, Pankaj ;

Escolar, Diana M. ;

Jackson, Aimee L. ;

Slack, Frank J. .

CLINICAL CANCER RESEARCH, 2021, 27 (04) :1139-1149

[5] Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas [J].

Anastasiadou, Eleni ;

Stroopinsky, Dina ;

Alimperti, Stella ;

Jiao, Alan L. ;

Pyzer, Athalia R. ;

Cippitelli, Claudia ;

Pepe, Giuseppina ;

Severa, Martina ;

Rosenblatt, Jacalyn ;

Etna, Marilena P. ;

Rieger, Simone ;

Kempkes, Bettina ;

Coccia, Eliana M. ;

Sui, Shannan J. Ho ;

Chen, Christopher S. ;

Uccini, Stefania ;

Avigan, David ;

Faggioni, Alberto ;

Trivedi, Pankaj ;

Slack, Frank J. .

LEUKEMIA, 2019, 33 (01) :132-147

[6] MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen [J].

Bai, Haitao ;

Wei, Ju ;

Deng, Chong ;

Yang, Xiaoyu ;

Wang, Chun ;

Xu, Rang .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (02) :223-231

[7] Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL [J].

Balinas-Gavira, Carlos ;

Rodriguez, Maria, I ;

Andrades, Alvaro ;

Cuadros, Marta ;

Carlos Alvarez-Perez, Juan ;

Alvarez-Prado, Angel F. ;

de Yebenes, Virginia G. ;

Sanchez-Hernandez, Sabina ;

Fernandez-Vigo, Elvira ;

Munoz, Javier ;

Martin, Francisco ;

Ramiro, Almudena R. ;

Martinez-Climent, Jose A. ;

Medina, Pedro P. .

LEUKEMIA, 2020, 34 (10) :2722-2735

[8] MicroRNAs: Target Recognition and Regulatory Functions [J].

Bartel, David P. .

CELL, 2009, 136 (02) :215-233

[9] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].

Bartel, David P. .

CELL, 2007, 131 (04) :11-29

[10] Roles of BCL6 in normal and transformed germinal center B cells [J].

Basso, Katia ;

Dalla-Favera, Riccardo .

IMMUNOLOGICAL REVIEWS, 2012, 247 :172-183

← 1 2 3 4 5 6 7 8 9 10 →